Ramucirumab trials for Recurrent Lung Non-Small Cell Carcinoma

All Ramucirumab trials · All Recurrent Lung Non-Small Cell Carcinoma trials

Phase breakdown

Recruiting trials studying Ramucirumab for Recurrent Lung Non-Small Cell Carcinoma

• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 386 locations
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 454 locations
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
  NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female) · 266 locations

Common questions

How many trials study Ramucirumab for Recurrent Lung Non-Small Cell Carcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.